Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy DrReddys Laboratories stock

Own DrReddys Laboratories stock in just a few minutes.

Fact checked

Dr. Reddy's Laboratories Limited is a drug manufacturers-specialty & generic business based in the US. DrReddys Laboratories shares (RDY) are listed on the NYSE and all prices are listed in US Dollars. DrReddys Laboratories employs 21,650 staff and has a market cap (total outstanding shares value) of USD$10.2 billion.

How to buy shares in DrReddys Laboratories

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for DrReddys Laboratories. Find the stock by name or ticker symbol: RDY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DrReddys Laboratories reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DrReddys Laboratories, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of DrReddys Laboratories. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

DrReddys Laboratories share price

Use our graph to track the performance of RDY stocks over time.

DrReddys Laboratories shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$33.1177 - USD$73.39
50-day moving average USD$67.1103
200-day moving average USD$65.9336
Wall St. target priceUSD$72.5
PE ratio 43.5328
Dividend yield USD$0.292 (0.48%)
Earnings per share (TTM) USD$1.404

Buy DrReddys Laboratories shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DrReddys Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is DrReddys Laboratories under- or over-valued?

Valuing DrReddys Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddys Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DrReddys Laboratories's P/E ratio

DrReddys Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, DrReddys Laboratories shares trade at around 44x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DrReddys Laboratories's PEG ratio

DrReddys Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4157. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddys Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DrReddys Laboratories financials

Gross profit TTM USD$94 billion
Return on assets TTM 8.56%
Return on equity TTM 13.37%
Profit margin 11.38%
Book value $11.575
Market capitalisation USD$10.2 billion

TTM: trailing 12 months

Shorting DrReddys Laboratories shares

There are currently 1.1 million DrReddys Laboratories shares held short by investors – that's known as DrReddys Laboratories's "short interest". This figure is 28.7% up from 845,264 last month.

There are a few different ways that this level of interest in shorting DrReddys Laboratories shares can be evaluated.

DrReddys Laboratories's "short interest ratio" (SIR)

DrReddys Laboratories's "short interest ratio" (SIR) is the quantity of DrReddys Laboratories shares currently shorted divided by the average quantity of DrReddys Laboratories shares traded daily (recently around 165033.08042489). DrReddys Laboratories's SIR currently stands at 6.59. In other words for every 100,000 DrReddys Laboratories shares traded daily on the market, roughly 6590 shares are currently held short.

However DrReddys Laboratories's short interest can also be evaluated against the total number of DrReddys Laboratories shares, or, against the total number of tradable DrReddys Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DrReddys Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DrReddys Laboratories shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable DrReddys Laboratories shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DrReddys Laboratories.

Find out more about how you can short DrReddys Laboratories stock.

DrReddys Laboratories share dividends

19%

Dividend payout ratio: 19.2% of net profits

Recently DrReddys Laboratories has paid out, on average, around 19.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddys Laboratories shareholders could enjoy a 0.53% return on their shares, in the form of dividend payments. In DrReddys Laboratories's case, that would currently equate to about $0.292 per share.

While DrReddys Laboratories's payout ratio might seem low, this can signify that DrReddys Laboratories is investing more in its future growth.

DrReddys Laboratories's most recent dividend payout was on 17 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 10 July 2020 (the "ex-dividend date").

Have DrReddys Laboratories's shares ever split?

DrReddys Laboratories's shares were split on a 2:1 basis on 7 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddys Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddys Laboratories shares which in turn could have impacted DrReddys Laboratories's share price.

DrReddys Laboratories share price volatility

Over the last 12 months, DrReddys Laboratories's shares have ranged in value from as little as $33.1177 up to $73.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddys Laboratories's is -0.0252. This would suggest that DrReddys Laboratories's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, DrReddys Laboratories has bucked the trend.

DrReddys Laboratories overview

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site